Eli Lilly
Another failure in Alzheimer’s creates bleak outlook for treatment
June 12, 2018Manufacturing and Production, Research and Development Alzheimer's, AstraZeneca, Eli Lilly, biotech, drugs, pharma, pharmaceutical
Finding a treatment for Alzheimer’s disease has been one of the aims of big pharma for last few decades, but …
Eli Lilly’s President of Oncology to retire
June 5, 2018Research and Development Cancer, Eli Lilly, appointment, oncology, pharma
Just as it ramps up its cancer-fighting efforts, Eli Lilly has revealed that its Senior Vice President and President of …
FDA greenlights Lilly’s Olumiant in rheumatoid arthritis, with major caveats
June 5, 2018Manufacturing and Production, Sales and Marketing Eli Lilly, FDA, Olumiant, pharma
Eli Lilly has announced that its oral JAK inhibitor Olumiant (baricitinib) has received FDA approval for the treatment of moderately-to-severely …
Lilly’s galcanezumab soars in episodic cluster headache, but fails in chronic form
May 16, 2018Research and Development Eli Lilly, galcanezumab, headache, migraine, pharma
Eli Lilly has released new Phase 3 results for its CGRP inhibitor galcanezumab in the treatment of episodic cluster headache, …
Lilly chalks up another acquisition with AurKa for $575m
May 14, 2018Manufacturing and Production, Sales and Marketing AurKa, Cancer, Eli Lilly, acquisition, oncology, pharma
Swiftly following up its $1.6 billion splash to pick up Armo BioSciences last week, Eli Lilly has agreed to acquire …
Lilly moves quickly to secure $1.6bn buyout of Armo
May 10, 2018Medical Communications, Sales and Marketing Armo Biosciences, Eli Lilly, biotech, drugs, pharma, pharmaceutical
Armo BioSciences only went public in January but it has already been snapped up by Eli Lilly for $1.6 billion. …
Lilly hires new leader of immuno-oncology
May 1, 2018Manufacturing and Production, Medical Communications Eli Lilly, biotech, drugs, immunoconlogy, immunotherapy, pharma, pharmaceutical
Immuno-oncology has become a huge area of the oncology market, led by the wave of PD-1/L1 drugs that are reaping …
Top Ten most popular articles on Pharmafile.com this week
April 27, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, FDA, Fresenius, Shire, Takeda, arthritis, pharma
The year seems like it’s running away as we come to the end of April. It’s been a more tense …
Eli Lilly partners with Chinese institution to advance the nation’s diabetes and CVD care
April 27, 2018Medical Communications, Research and Development China, Eli Lilly, cardiovascular disorders, cvd, diabetes, pharma, type 2 diabetes
EIi Lilly has announced plans to partner up with China’s National Center for Cardiovascular Diseases (NCCD), the nation’s institution responsible …
Lilly’s arthritis drug found to prevent potentially lethal stem cell transplant complications
April 25, 2018Research and Development Cancer, Eli Lilly, JAK inhibitors, Stem cells, baricitinib, graft-versus-host disease, pharma
Researchers at St Louis Washington University School of Medicine have uncovered a promising extra application of a particular Janus Kinase …
Lilly’s arthritis drug hits trouble at FDA committee
April 24, 2018Manufacturing and Production, Sales and Marketing Eli Lilly, Incyte, biotech, drugs, pharma, pharmaceutical, rheumatoid arthritis
FDA’s advisory committee were openly conflicted about deciding on the safety of Eli Lilly and Incyte’s drug, baricitinib, for the …
Lilly and Incyte’s resubmission of arthritis drug data fails to assuage FDA concerns
April 20, 2018Medical Communications, Sales and Marketing Eli Lilly, FDA, Incyte, baricitinib, pharma, rheumatoid arthritis
Eli Lilly and Incyte are facing more complications in the US approval of their experimental rheumatoid arthritis (RA) drug baricitinib …
Lilly and Sigilon team up in $473m+ deal to ‘cure’ diabetes
April 5, 2018Sales and Marketing Eli Lilly, Sigilon Therapeutics, biotech, drugs, pharma, pharmaceutical
Eli Lilly and Sigilon Therapeutics have announced a partnership that looks to break new ground in the management of type …
Anthera pulls the plug on Sollpura after Phase 3 failure, shares plummet 84%
March 13, 2018Manufacturing and Production, Research and Development Anthera, Eli Lilly, Sollpura, pharma, trial failure
Anthera Pharmaceuticals has announced that it is to terminate development of its investigational pancreatic enzyme replacement therapy (PERT) Sollpura after …
FDA expands indication of Lilly’s Verzenio in advanced breast cancer
February 27, 2018Manufacturing and Production, Sales and Marketing Cancer, Eli Lilly, FDA, Verzenio, breast cancer, pharma
Eli Lilly is celebrating the news that its cyclin-dependent kinase (CDK) 4 & 6 inhibitor Verzenio (ademaciclib) has received approval …
Latest content
Five Facts about cardiovascular disease
